The dysplastic nevus: from historical perspective to management in the modern era: part II. Molecular aspects and clinical management.
暂无分享,去创建一个
[1] D. Bennett. Human melanocyte senescence and melanoma susceptibility genes , 2003, Oncogene.
[2] S. Leachman,et al. Response to Gray-Schopfer et al. and Michaloglou et al. , 2008 .
[3] A. Marghoob,et al. Treatment of dysplastic nevi with 5% imiquimod cream, a pilot study. , 2006, Journal of drugs in dermatology : JDD.
[4] D. Margolis,et al. Variability in nomenclature used for nevi with architectural disorder and cytologic atypia (microscopically dysplastic nevi) by dermatologists and dermatopathologists , 2004, Journal of cutaneous pathology.
[5] W. Westra,et al. Distribution of BRAF T1799A(V600E) Mutations Across Various Types of Benign Nevi: Implications for Melanocytic Tumorigenesis , 2007, The American Journal of dermatopathology.
[6] S. Cramer. War and peace in the Realm of Dysplastic Nevi , 2005, Journal of cutaneous pathology.
[7] M. Shoup,et al. Predictors of positive sentinel lymph node in thin melanoma. , 2011, American journal of surgery.
[8] K. Arndt,et al. Laser treatment of pigmented lesions--2000: how far have we gone? , 2000, Archives of dermatology.
[9] T. Spector,et al. Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi , 2009, Nature Genetics.
[10] F. Meyskens,et al. Effect of oral isotretinoin on dysplastic nevi. , 1989, Journal of the American Academy of Dermatology.
[11] M. Martinka,et al. Prognostic significance of RUNX3 expression in human melanoma , 2011, Cancer.
[12] W. Clark,et al. Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'. , 1978, Archives of dermatology.
[13] S. Florell,et al. Proliferation, apoptosis, and survivin expression in a spectrum of melanocytic nevi , 2005, Journal of cutaneous pathology.
[14] W. Clark,et al. Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/DN) on chromosome 1p, and evidence for genetic heterogeneity. , 1993, American journal of human genetics.
[15] N. Hayward,et al. A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation , 2005, Genes, chromosomes & cancer.
[16] A. Marghoob,et al. Management of dysplastic nevi: a survey of fellows of the American Academy of Dermatology. , 2002, Journal of the American Academy of Dermatology.
[17] M. Martinka,et al. Treatment of atypical nevi with imiquimod 5% cream. , 2007, Archives of dermatology.
[18] A. H. Diwan,et al. Phosphoinositide 3‐kinase is not overexpressed in melanocytic lesions , 2007, Journal of cutaneous pathology.
[19] A. Elefanty,et al. Human acquired naevi are clonal , 1998, Melanoma research.
[20] G. Botti,et al. Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma , 2007, The British journal of dermatology.
[21] A. Wojas-Pelc,et al. Cyclin D1 and D3 expression in melanocytic skin lesions , 2010, Archives of Dermatological Research.
[22] S. H. Kim,et al. Genetic alterations of p16INK4a and p53 genes in sporadic dysplastic nevus. , 1997, Biochemical and biophysical research communications.
[23] G. Screaton,et al. Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand. , 2006, Human pathology.
[24] P. Meltzer,et al. High frequency of BRAF mutations in nevi , 2003, Nature Genetics.
[25] J. Simon,et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[26] C. Lewis,et al. A multiobserver, population-based analysis of histologic dysplasia in melanocytic nevi. , 1994, Journal of the American Academy of Dermatology.
[27] P. Green,et al. Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. , 1989, The New England journal of medicine.
[28] B. Bates. With Dysplastic Nevi, Pause Before You Biopsy , 2006 .
[29] A. Kopf. What Is Early Melanoma? , 1993, The American Journal of dermatopathology.
[30] D. Pinkel,et al. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. , 2000, The American journal of pathology.
[31] G. Annessi,et al. Correlation between clinical atypia and histologic dysplasia in acquired melanocytic nevi. , 2001, Journal of the American Academy of Dermatology.
[32] D. Grossman,et al. Strategies for early melanoma detection: Approaches to the patient with nevi. , 2009, Journal of the American Academy of Dermatology.
[33] W. Clark,et al. Lack of association between intraocular melanoma and cutaneous dysplastic nevi. , 1984, American journal of ophthalmology.
[34] C. Sherr. Cancer Cell Cycles , 1996, Science.
[35] D. Barnes,et al. p53 immunoreactivity in human malignant melanoma and dysplastic naevi , 1993, The British journal of dermatology.
[36] T. Venesio,et al. Altered molecular pathways in melanocytic lesions , 2010, International journal of cancer.
[37] P. Duray,et al. Loss of heterozygosity detected on 1p and 9q in microdissected atypical nevi. , 1998, Archives of dermatology.
[38] Michael R. Green,et al. Role for IGFBP7 in Senescence Induction by BRAF , 2010, Cell.
[39] R. Barr,et al. Histologic atypia in clinically benign nevi. A prospective study. , 1990, Journal of the American Academy of Dermatology.
[40] R. Anderson,et al. Treatment of benign and atypical nevi with the normal-mode ruby laser and the Q-switched ruby laser: clinical improvement but failure to completely eliminate nevomelanocytes. , 1999, Archives of dermatology.
[41] S. Cessie,et al. Effect of topical tretinoin under occlusion on atypical naevi , 1998, Melanoma research.
[42] W. Clark,et al. National Institutes of Health Consensus Development Conference Statement on Diagnosis and Treatment of Early Melanoma, January 27–29, 1992 , 1993 .
[43] M. Hurt. The melanocytic nevus described by Clark et al. What is its nature? What should it be named? An answer from history and from logic , 2005, Journal of cutaneous pathology.
[44] W. Bergman,et al. Ocular melanoma in families with dysplastic nevus syndrome. , 1990, Journal of the American Academy of Dermatology.
[45] B. Lebe,et al. The Significance of Ki-67 Proliferative Index and Cyclin D1 Expression of Dysplastic Nevi in the Biologic Spectrum of Melanocytic Lesions , 2007, Applied immunohistochemistry & molecular morphology : AIMM.
[46] W. Clark,et al. Topical chemotherapy of dysplastic melanocytic nevi with 5% fluorouracil. , 1981, Archives of dermatology.
[47] Michael R. Green,et al. Oncogenic BRAF-positive dysplastic nevi and the tumor suppressor IGFBP7--challenging the concept of dysplastic nevi as precursor lesions? , 2010, Human pathology.
[48] S. Leachman,et al. Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo. , 2007, The Journal of investigative dermatology.
[49] G. Enders,et al. p16INK4a can initiate an autonomous senescence program , 2000, Oncogene.
[50] M. Piepkorn,et al. Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions. , 1998, The Journal of investigative dermatology.
[51] G. Wood,et al. Comprehensive analysis of 112 melanocytic skin lesions demonstrates microsatellite instability in melanomas and dysplastic nevi, but not in benign nevi , 2001, Journal of cutaneous pathology.
[52] A. Ackerman,et al. Pseudomelanoma: recurrent melanocytic nevus following partial surgical removal. , 1975, Archives of dermatology.
[53] T. Batinac,et al. Expression of cell cycle and apoptosis regulatory proteins and telomerase in melanocitic lesions. , 2007, Collegium antropologicum.
[54] D. Levin,et al. Detection of p53 mutations in benign and dysplastic nevi. , 1995, Cancer research.
[55] M. van de Rijn,et al. bcl-2 expression in melanocytic nevi. Insights into the biology of dermal maturation. , 1995, Archives of dermatology.
[56] J. Becker,et al. Germline mutations in BAP1 predispose to melanocytic tumors , 2011, Nature Genetics.
[57] T. Alanko,et al. FGF expression allows nevus cells to survive in three-dimensional collagen gel under conditions that induce apoptosis in normal human melanocytes. , 1999, The Journal of investigative dermatology.
[58] W. Clark,et al. A natural history of melanomas and dysplastic nevi , 2002, Cancer.
[59] R. Presland,et al. A search for CDKN2A/p16INK4a mutations in melanocytic nevi from patients with melanoma and spouse controls by use of laser-captured microdissection. , 2005, Archives of dermatology.
[60] W. Clark,et al. Two-locus linkage analysis of cutaneous malignant melanoma/dysplastic nevi. , 1996, American journal of human genetics.
[61] D. Bennett,et al. Comment on "Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo". , 2008, The Journal of investigative dermatology.
[62] C. Bartoli,et al. Detection of microsatellite alterations in the spectrum of melanocytic nevi in patients with or without individual or family history of melanoma , 2000, International journal of cancer.
[63] Michael R. Green,et al. Oncogenic BRAF Induces Senescence and Apoptosis through Pathways Mediated by the Secreted Protein IGFBP7 , 2008, Cell.
[64] E. R. Farmer,et al. NIH Consensus conference. Diagnosis and treatment of early melanoma. , 1992, JAMA.
[65] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[66] J. Naeyaert,et al. Inter‐observer variation in the histopathological diagnosis of clinically suspicious pigmented skin lesions , 2002, The Journal of pathology.
[67] N. Smit,et al. Increased Melanogenesis is a Risk Factor for Oxidative DNA Damage— Study on Cultured Melanocytes and Atypical Nevus Cells † , 2008, Photochemistry and photobiology.
[68] H. Ananthaswamy,et al. P53 protein and pathogenesis of melanoma and nonmelanoma skin cancer. , 2008, Advances in experimental medicine and biology.
[69] D. Pinkel,et al. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. , 2007, The Journal of investigative dermatology.
[70] J. Kelly,et al. A high incidence of melanoma found in patients with multiple dysplastic naevi by photographic surveillance , 1997, The Medical journal of Australia.
[71] F. Kiesewetter,et al. Differentiation between Spitz nevi and malignant melanomas by interphase fluorescence in situ hybridization. , 1999, International journal of oncology.
[72] P. Uribe,et al. Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi. , 2006, The Journal of investigative dermatology.
[73] R. Parsons,et al. The role of PTEN signaling perturbations in cancer and in targeted therapy , 2008, Oncogene.
[74] L. Liotta,et al. Allelic deletion at chromosome 9p21(p16) and 17p13(p53) in microdissected sporadic dysplastic nevus. , 1998, Human pathology.
[75] J. Radhi. Malignant Melanoma Arising from Nevi, p53, p16, and Bcl-2: Expression in Benign versus Malignant Components , 1999, Journal of cutaneous medicine and surgery.
[76] R. Marais,et al. Cellular senescence in naevi and immortalisation in melanoma: a role for p16? , 2006, British Journal of Cancer.
[77] R. Barr,et al. Analysis of heterogeneity of atypia within melanocytic nevi. , 2003, Archives of dermatology.
[78] Yu Fang,et al. Fluorescence in Situ Hybridization for Distinguishing Nevoid Melanomas From Mitotically Active Nevi , 2009, The American journal of surgical pathology.
[79] John Calvin Reed,et al. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma. , 1995, The American journal of pathology.
[80] Gary S. Rogers,et al. Diagnosis and Treatment of Early Melanoma: NIH Consensus Development Panel on Early Melanoma , 1992 .
[81] D. Weiss,et al. Mutational analysis of N-ras, p53, CDKN2A (p16INK4a), p14ARF, CDK4, and MC1R genes in human dysplastic melanocytic naevi , 2003, Journal of medical genetics.
[82] M. Nasr,et al. Comparison of pHH3, Ki-67, and Survivin Immunoreactivity in Benign and Malignant Melanocytic Lesions , 2008, The American Journal of dermatopathology.
[83] T. Papp,et al. Mutational analysis of the BRAF gene in human congenital and dysplastic melanocytic naevi , 2005, Melanoma research.
[84] H. Breuninger,et al. Dysplastic nevus syndrome with development of multiple melanomas. A surgical concept for prophylaxis , 2009, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[85] A Halpern,et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. , 1997, JAMA.
[86] H. Koerten,et al. Disturbed melanin synthesis and chronic oxidative stress in dysplastic naevi. , 2004, European journal of cancer.
[87] J. Shay,et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi , 2005, Nature.
[88] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[89] Ackerman Ab. A critique of an N.I.H. Consensus Development Conference about "early" melanoma. , 1993 .
[90] C. Shea,et al. Clinical decision making based on histopathologic grading and margin status of dysplastic nevi. , 2012, Archives of dermatology.
[91] J. McNiff,et al. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. , 1999, The Journal of investigative dermatology.
[92] D. Peeper,et al. Oncogene-induced cell senescence--halting on the road to cancer. , 2006, The New England journal of medicine.
[93] M. Mihm,et al. PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma. , 2003, Journal of the American Academy of Dermatology.
[94] D. Peeper,et al. Comment on "Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo". , 2008, The Journal of investigative dermatology.
[95] S. Florell,et al. Low rates of clinical recurrence after biopsy of benign to moderately dysplastic melanocytic nevi. , 2010, Journal of the American Academy of Dermatology.
[96] A. Emley,et al. BRAF V600E mutation and the tumour suppressor IGFBP7 in atypical genital naevi , 2010, The British journal of dermatology.
[97] E. Glusac. What to call the LEJC‐BFV nevus? , 2004, Journal of cutaneous pathology.
[98] J. Grichnik. Dermoscopy of melanocytic neoplasms: subpatterns of dysplastic/atypical nevi. , 2003, Archives of dermatology.
[99] D. Massi,et al. A new concept of melanocytic neoplasia pathogenesis based on the phenotype of common acquired nevi. , 2007, Medical hypotheses.
[100] M. Mihm,et al. Recurrent nevus phenomenon: a clinicopathologic study of 357 cases and histologic comparison with melanoma with regression , 2009, Modern Pathology.
[101] I. Newsham,et al. Alteration of chromosome 9p21 and/or p16 in benign and dysplastic nevi suggests a role in early melanoma progression (United States) , 2002, Cancer Causes & Control.